These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23553586)

  • 1. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.
    Tacelli N; Santangelo T; Scherpereel A; Duhamel A; Deken V; Klotz E; Cortot A; Lafitte JJ; Wallyn F; Remy J; Remy-Jardin M
    Eur Radiol; 2013 Aug; 23(8):2127-36. PubMed ID: 23553586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects.
    Fraioli F; Anzidei M; Serra G; Liberali S; Fiorelli A; Zaccagna F; Longo F; Anile M; Catalano C
    Br J Radiol; 2013 Sep; 86(1029):20120174. PubMed ID: 23908346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
    Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
    Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy.
    Ohno Y; Koyama H; Fujisawa Y; Yoshikawa T; Seki S; Sugihara N; Sugimura K
    Eur J Radiol; 2016 Jan; 85(1):176-186. PubMed ID: 26724663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.
    Fraioli F; Anzidei M; Zaccagna F; Mennini ML; Serra G; Gori B; Longo F; Catalano C; Passariello R
    Radiology; 2011 May; 259(2):574-82. PubMed ID: 21357523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?
    Kim YN; Lee HY; Lee KS; Seo JB; Chung MJ; Ahn MJ; Park K; Kim TS; Yi CA
    Korean J Radiol; 2012; 13(6):702-10. PubMed ID: 23118568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC).
    Trinidad López C; De La Fuente Aguado J; Oca Pernas R; Delgado Sánchez-Gracián C; Santos Armentia E; Vaamonde Liste A; Prada González R; Souto Bayarri M
    Eur Radiol Exp; 2019 Jun; 3(1):23. PubMed ID: 31197486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.
    Yip C; Tacelli N; Remy-Jardin M; Scherpereel A; Cortot A; Lafitte JJ; Wallyn F; Remy J; Bassett P; Siddique M; Cook GJ; Landau DB; Goh V
    J Thorac Imaging; 2015 Sep; 30(5):300-7. PubMed ID: 26164165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
    Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
    Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of whole-tumor dual-input perfusion CT in predicting the effect of multiarterial infusion chemotherapy on advanced non-small cell lung cancer.
    Li XS; Fan HX; Fang H; Huang H; Song YL; Zhou CW
    AJR Am J Roentgenol; 2014 Nov; 203(5):W497-505. PubMed ID: 25341164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
    Hwang SH; Yoo MR; Park CH; Jeon TJ; Kim SJ; Kim TH
    Eur Radiol; 2013 Jun; 23(6):1573-81. PubMed ID: 23300040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
    Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
    Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
    AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
    Van der Veldt AA; Lubberink M; Bahce I; Walraven M; de Boer MP; Greuter HN; Hendrikse NH; Eriksson J; Windhorst AD; Postmus PE; Verheul HM; Serné EH; Lammertsma AA; Smit EF
    Cancer Cell; 2012 Jan; 21(1):82-91. PubMed ID: 22264790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy.
    Wang J; Wu N; Cham MD; Song Y
    AJR Am J Roentgenol; 2009 Oct; 193(4):1090-6. PubMed ID: 19770333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.
    Yabuuchi H; Kawanami S; Iwama E; Okamoto I; Kamitani T; Sagiyama K; Yamasaki Y; Honda H
    Radiology; 2018 Feb; 286(2):685-695. PubMed ID: 29059037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.